Donald Lloyd-Jones, MD, ScM, the Eileen M. Foell Professor, has introduced that he will probably be stepping down as chair of the Division of Preventive Drugs on the finish of this tutorial 12 months, after 15 years of service within the position.
Donald Lloyd-Jones, MD, ScM, the Eileen M. Foell Professor, has introduced that he will probably be stepping down as chair of the Division of Preventive Drugs on the finish of this tutorial 12 months, after 15 years of distinguished management within the position. Since taking the helm in 2009, the division has grown tremendously, rising to the primary NIH-funded public well being division of its form, and internationally acknowledged as a premier vacation spot for preventive drugs and inhabitants well being.
“Serving as chair of this division has been the chance of a lifetime,” Lloyd-Jones stated. “From its formation by Jerry Stamler greater than 50 years in the past to at this time, you possibly can see the thread of analysis and coaching that has influenced and remodeled the sector of preventive drugs. I’m proud to be a part of that legacy and to have championed wonderful science and collaboration. We’ve got educated generations of actually excellent preventive and inhabitants well being scientists, and to see their success is what I’m most pleased with as a departmental legacy.”
Initially based in 1972 as a small crew of fewer than 10 individuals, the division has grown to incorporate seven divisions with 302 college and employees. It’s comprised of school from an array of scientific disciplines: epidemiologists, diet and behavioral scientists, biostatisticians, informaticians, public well being practitioners, clinicians, and extra, all working collaboratively to affect illness prevention and well being promotion throughout the life course. Within the 2022-2023 12 months, the division acquired greater than $44 million in analysis funding and awards, its highest ever.
Recruited to the division in 2004 from Harvard Medical College and Massachusetts Basic Hospital, Lloyd-Jones was an energetic early profession investigator on the long-running Framingham Coronary heart Examine. Whereas at Feinberg, along with his position as chair, he was senior affiliate dean for scientific and translational Sciences analysis and director of the NUCATS Institute from 2012 to 2020. From 2021 to 2022, he additionally served as president of the American Coronary heart Affiliation. A prolific scientist, he has printed 788 peer-reviewed publications to this point and usually is listed among the many prime 1 p.c of extremely cited researchers who’ve “demonstrated vital and broad affect” by Clarivate Analytics.
Lloyd-Jones’ analysis pursuits embrace the examine of the mechanisms and life course of cardiovascular well being and wholesome growing older, and heart problems epidemiology and prevention. A primary focus of his analysis has been investigation of the life course and mechanisms of persistent ailments of growing older, lifetime dangers for varied cardiovascular ailments, and components which modify these dangers. Different areas of curiosity embrace heart problems threat estimation utilizing novel biomarkers, imaging of subclinical atherosclerosis, and the epidemiology and outcomes of hypertension and dyslipidemia. His scientific and educating pursuits lie generally cardiology, with a deal with prevention.
“Don has been an incredible drive as chair of Preventive Drugs; his spectacular accomplishments and impactful physique of analysis are exemplar,” stated Eric G. Neilson, MD, vice chairman for medical affairs and Lewis Landsberg Dean. “However most hanging about working with Don, is what Jerry Stamler stated about him in 2009 – ‘he’s sharp, level-headed, heat and optimistic.’ He has set the bar excessive for everybody within the division, and he’s carried out it by championing individuals and function. We’re grateful for his years of considerate management, and I do know his legacy as chair will probably be warmly remembered and handed on for generations.”
Lloyd-Jones will keep on as chair of the division till a brand new chair has been chosen. After stepping down, he’ll stay a member of the college within the departments of Preventive Drugs, Drugs, and Pediatrics, and proceed his scientific observe and analysis, together with serving to lead two giant research specializing in understanding the affect of maternal well being throughout being pregnant and of social determinants of well being from start on trajectories of cardiovascular well being into maturity. He and his crew additionally lately acquired funding from NIH for 10 extra years of the longstanding Coronary Artery Danger Improvement in Younger Adults Examine, which started in 1985.
A graduate of Swarthmore School, Lloyd-Jones acquired his Physician of Drugs diploma from Columbia College School of Physicians and Surgeons in 1991 and his Grasp of Science diploma in epidemiology from the Harvard College of Public Well being in 2001. He’s a fellow of the American School of Cardiology and the American Coronary heart Affiliation and has acquired quite a few prestigious awards and honors.
